JP5340393B2 - 腎細胞癌の治療のための３，３’，４，４’−テトラヒドロキシ−２，２’−ビピリジン−ｎ，ｎ’−ジオキシド - Google Patents

腎細胞癌の治療のための３，３’，４，４’−テトラヒドロキシ−２，２’−ビピリジン−ｎ，ｎ’−ジオキシド Download PDF

Info

Publication number
JP5340393B2
JP5340393B2 JP2011529583A JP2011529583A JP5340393B2 JP 5340393 B2 JP5340393 B2 JP 5340393B2 JP 2011529583 A JP2011529583 A JP 2011529583A JP 2011529583 A JP2011529583 A JP 2011529583A JP 5340393 B2 JP5340393 B2 JP 5340393B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
formula
acid
olelanin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011529583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504584A (ja
JP2012504584A5 (cg-RX-API-DMAC10.html
Inventor
ナイストレム、ジェニー
ブバル、リサ
ニルソン、ウルフ
ハラルドソン、ボリエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2012504584A publication Critical patent/JP2012504584A/ja
Publication of JP2012504584A5 publication Critical patent/JP2012504584A5/ja
Application granted granted Critical
Publication of JP5340393B2 publication Critical patent/JP5340393B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011529583A 2008-10-06 2009-10-06 腎細胞癌の治療のための３，３’，４，４’−テトラヒドロキシ−２，２’−ビピリジン−ｎ，ｎ’−ジオキシド Active JP5340393B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19531208P 2008-10-06 2008-10-06
US61/195,312 2008-10-06
US12/586,849 US8053430B2 (en) 2008-10-06 2009-09-29 Treatment of renal cell carcinoma
US12/586,849 2009-09-29
PCT/EP2009/062976 WO2010040750A1 (en) 2008-10-06 2009-10-06 3, 3', 4, 4' -tetrahydroxy-2, 2' -bipyridine-n, n' -dioxides for the treatment of renal cell carcinoma

Publications (3)

Publication Number Publication Date
JP2012504584A JP2012504584A (ja) 2012-02-23
JP2012504584A5 JP2012504584A5 (cg-RX-API-DMAC10.html) 2012-12-06
JP5340393B2 true JP5340393B2 (ja) 2013-11-13

Family

ID=41395600

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011529583A Active JP5340393B2 (ja) 2008-10-06 2009-10-06 腎細胞癌の治療のための３，３’，４，４’−テトラヒドロキシ−２，２’−ビピリジン−ｎ，ｎ’−ジオキシド

Country Status (11)

Country Link
US (2) US8053430B2 (cg-RX-API-DMAC10.html)
EP (1) EP2349268B1 (cg-RX-API-DMAC10.html)
JP (1) JP5340393B2 (cg-RX-API-DMAC10.html)
KR (1) KR101678702B1 (cg-RX-API-DMAC10.html)
CN (2) CN102170881B (cg-RX-API-DMAC10.html)
CA (1) CA2736322C (cg-RX-API-DMAC10.html)
DK (1) DK2349268T3 (cg-RX-API-DMAC10.html)
ES (1) ES2401671T3 (cg-RX-API-DMAC10.html)
PL (1) PL2349268T3 (cg-RX-API-DMAC10.html)
PT (1) PT2349268E (cg-RX-API-DMAC10.html)
WO (1) WO2010040750A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2552443B1 (en) * 2010-04-01 2021-07-14 Oncorena Ab Improved treatment of renal cell carcinoma
GB201103578D0 (en) * 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
CN105450495B (zh) * 2014-09-18 2018-09-21 中国电信股份有限公司 用于重新建立安全通信通道的方法、装置和系统
WO2024002909A1 (en) 2022-07-01 2024-01-04 Oncorena Ab Orellanine formulation
CN121335885A (zh) 2023-05-03 2026-01-13 奥科瑞纳股份公司 奥来毒素的合成
KR20250083338A (ko) 2023-11-30 2025-06-10 가톨릭대학교 산학협력단 신장암 어셈블로이드 및 이의 제조 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713352A (en) 1981-08-31 1987-12-15 Sloan-Kettering Institute For Cancer Reseach Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
US6403373B1 (en) 1997-10-10 2002-06-11 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon, renal, and stomach cancer and methods of using these
US6440663B1 (en) 1998-10-05 2002-08-27 Ludwig Institute For Cancer Research Renal cancer associated antigens and uses therefor
AR029160A1 (es) 1999-04-08 2003-06-18 Schering Corp El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
CN1359941A (zh) 2000-12-20 2002-07-24 上海博德基因开发有限公司 一种新的多肽——人肾癌rage4抗原11.44和编码这种多肽的多核苷酸
RU2188026C1 (ru) 2001-01-12 2002-08-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака почки
EP1712234B1 (en) 2001-09-12 2009-01-28 Novartis AG Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment
ATE537842T1 (de) 2002-07-01 2012-01-15 Wilex Ag Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms
DE10307928A1 (de) 2003-02-25 2004-09-16 Faustus Forschungs Cie. Translational Cancer Research Gmbh Verwendung von 1-(2-Chlorethyl)-1-nitroso-3-(2-hydroxyethyl)-urea zur Behandlung von Pankreaskarzinomen, Weichteilsarkomen, Hodentumoren, Lymphomen, Thymomen, Wilms Tumoren, Nierenkarzinomen, Melanomen, Lungentumoren, intracerebralen Metastasen, Tumoren im Kopf- und Halsbereich, und Mamma-Karzinomen
WO2006044779A1 (en) 2004-10-14 2006-04-27 Northwestern University Detection and treatment of renal cancer
CA2625741C (en) 2005-10-14 2013-08-06 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Treating renal cancer using 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde
EP1957115B8 (en) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen

Also Published As

Publication number Publication date
US20100152243A1 (en) 2010-06-17
EP2349268A1 (en) 2011-08-03
CA2736322C (en) 2017-01-10
KR20110073486A (ko) 2011-06-29
PL2349268T3 (pl) 2013-06-28
CA2736322A1 (en) 2010-04-15
CN105147683A (zh) 2015-12-16
WO2010040750A1 (en) 2010-04-15
HK1218857A1 (zh) 2017-03-17
US20120077846A1 (en) 2012-03-29
ES2401671T3 (es) 2013-04-23
KR101678702B1 (ko) 2016-11-22
JP2012504584A (ja) 2012-02-23
DK2349268T3 (da) 2013-04-15
CN105147683B (zh) 2019-01-22
CN102170881A (zh) 2011-08-31
PT2349268E (pt) 2013-04-02
EP2349268B1 (en) 2013-01-16
US8349823B2 (en) 2013-01-08
CN102170881B (zh) 2015-07-22
HK1161116A1 (zh) 2012-08-24
US8053430B2 (en) 2011-11-08

Similar Documents

Publication Publication Date Title
US8003105B2 (en) Method of treating cancer by co-administration of anticancer agents
JP5806210B2 (ja) 癌または前癌状態を治療するための組み合わせ方法
EP4108242B1 (en) Pharmaceutical composition for preventing or treating cancer, containing mtor-signaling inhibitor as active ingredient
US8349823B2 (en) Treatment of renal cell carcinoma
JP2023533485A (ja) 重症型の肺高血圧症の治療方法
WO2014142220A1 (ja) 抗腫瘍剤
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
JP6197065B2 (ja) 腎細胞癌の改良された治療
RU2724341C1 (ru) Комбинированная композиция для предупреждения или лечения рака, содержащая производные бензофенонтиазола в качестве vda и ингибитор топоизомеразы
HK1218857B (en) 3, 3', 4, 4' -tetrahydroxy-2, 2' -bipyridine-n, n'-dioxides for the treatment of renal cell carcinoma
HK1161116B (en) 3, 3' 4, 4' -tetrahydroxy-2,2'-bipyridine-n, n'-dioxides for the treatment of renal cell carcinoma
HK40122790A (en) Methods and uses for treating cancer
Kang et al. 17-allylamino-demethoxygeldanamycin (17AAG) to inhibit growth in adenocarcinoma in lung cancer with nonphosphorylated mesenchymal-epithelial transition factor (MET)
JP2016104704A (ja) 抗腫瘍剤
JP2006507319A (ja) 中皮腫の処置

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121016

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20121016

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20121101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130531

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130621

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130703

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130806

R150 Certificate of patent or registration of utility model

Ref document number: 5340393

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250